Skip to content

Dr. Jules Demuynck

Active Private limited companyfounded 2023active for 3 yearsDendermondsesteenweg 253, 9040 GhentKBO/BCE: BE 0799.645.234

Lifetime

3 annual accounts with figures on one time axis
peak of €92,096 in 2025
€92,096▲ 7.3%
peak of €72,288 in 2025
€72,288▲ 8.1%
peak of €175,882 in 2025
€175,882▲ 69.8%
€15,430▼ 46.7%
Board1 name since 2023
1 director
Documentsfilings and deeds
29-07-20262 days before the deadline
2025micro format
Equity from €103,595 to €175,882Debts from €28,937 to €15,430Investments €5,781Cash from €22,289 to €7,329

Key points

from the 2025 annual accounts

Equity

€175,882 ▲ 69.8%
€104,0002024€176,0002025

Equity rose in 2025 from €103,595 to €175,882.

Turnover

≈ €200,000 estimated

The micro format states no turnover.

Investments

€6,939 3.2 times depreciation
202320242025

Green is investment, beige is depreciation.

Liquidity

12.62 was 4.58 in 2024

Short-term debts fell from €27,828 to €14,458.

Position in the sector

91.9%

Higher solvency than 86% of companies in human health. Sector median 63.0% · 21,347 companies.

Checked score

Bankruptcy probability within 12 months

Financial strength

Score breakdown

Comparable companies, two years later

In July 2024, 39,329 companies had the same profile as Dr. Jules Demuynck has now. Each dot stands for 99 companies, two years later.

95.7%
were still trading
2.4%
stopped another way
1.8%
went bankrupt
  • Micro
  • 2 to 5 years old
  • solvency 30% or more
  • a profit of 5% of the balance sheet or more

Another 0.1% stopped without a precise date, possibly only after those two years.

Test of the method

The method was tested on the 497,962 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.3% 0.5%
3 0.5% 0.6%
4 0.7% 0.8%
5 0.9% 0.9%
6 1.3% 1.5%
7 1.6% 1.8%
8 1.8% 1.8%
9 2.9% 3.1%
10 5.6% 6.1%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 39,329 companies, not a prediction for Dr. Jules Demuynck. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit verdict

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Board and ownership

Director
  • founderdeed of 21-03-2023
Board & ownership

Recent changes

Registered in the Peppol Directory Reachable for e-invoices through 0208:0799645234
Incorporation Founding capital of €2,500, 100 shares · Founded by · appointed as director · published on 21-03-2023 · Gazette deed
First establishment Dendermondsesteenweg 253, Ghent
All 10 events

Comparable companies

same main activity, similar in size and age
Company
Dr. Jules Demuynck Ghent €191,312 €92,096 91.9% -
DR. CHARLOTTE PAS, HUISARTS Zulte €198,744 €96,461 89.0% -
Dr. Monbailliu sportgeneeskunde en huisartsgeneeskunde Deinze €190,256 €99,676 76.7% -
DR. Wouter Cortens, Huisarts Destelbergen €203,156 €96,371 1.0% -
Huisarts Dr. Katrien Ceulemans Lokeren €192,859 €84,728 91.5% -
Dokter Sophie De Bock, huisarts Merelbeke-Melle €167,688 €89,387 1.2% -
Dr. Elizabet Damen, pediater Aalst €208,622 €82,617 88.3% -

These companies have the same main activity as Dr. Jules Demuynck: general medical practice (NACE 86210). They are comparable in size and age: total assets between €168,000 and €209,000, founded between 2022 and 2023.

Official details

Source: KBO
Status
Active since 17-03-2023Normal situation
Activity
General medical practiceNACE 86210and 1 other
Establishment unit
2.343.240.7779040 Ghent, since 17-03-2023
Financial year end
31 December
Peppol
Reachable since 31-01-2026
Company details

Annual accounts 2025

€191,312▲ 44.4%
Filing
Filed on 29-07-2026, 2 days before the end of the filing period
Financials

Insights on Dr. Jules Demuynck

Dr. Jules Demuynck files the micro format. That format states no turnover. The gross margin rose from €44,258 in 2023 to €92,096 in 2025.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.

Key facts about Dr. Jules Demuynck

What is the company number of Dr. Jules Demuynck?
The company number of Dr. Jules Demuynck is 0799.645.234. The VAT number is the same number with BE in front: BE 0799.645.234.
Where is Dr. Jules Demuynck based?
The registered office is at Dendermondsesteenweg 253, 9040 Ghent.Company details
What does Dr. Jules Demuynck do?
According to the KBO register, the main activity is general medical practice (NACE 86210).
What is the legal form of Dr. Jules Demuynck?
Dr. Jules Demuynck is a private limited company (BV).
When was Dr. Jules Demuynck founded?
Dr. Jules Demuynck was founded on 17-03-2023.
Is Dr. Jules Demuynck still active?
Yes, Dr. Jules Demuynck is an active enterprise in the KBO register.
What is the turnover of Dr. Jules Demuynck?
The turnover in financial year 2025 is ≈ €200,000. This figure is estimated from the gross margin of €92,096 and 33 comparable companies (NACE 862). It probably lies between €160,000 and €260,000.Financials
Is Dr. Jules Demuynck profitable?
In financial year 2025, Dr. Jules Demuynck made a profit of €72,288.
Where can I find the annual accounts of Dr. Jules Demuynck?
Dr. Jules Demuynck filed 3 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of Dr. Jules Demuynck due?
Dr. Jules Demuynck must file the annual accounts for financial year 2026 by 31-07-2027.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.